Drug Availability Update
Further to DrugAlert Vol 548, HPS Pharmacies wish to give notice that Pfizer is experiencing a supply interruption for gentamicin ampoules as follows:
Pfizer Gentamicin Injection BP
Gentamicin (as sulfate) 80mg/2mL
Normal supplies are expected to resume by end April 2021. An internationally registered brand of gentamicin (as sulfate) 80mg/2mL has been approved for supply under Section 19A of the Therapeutic Goods Act 1989.
This alternative product is a suitable option in most situations. However, clinicians are advised that this product contains the preservatives sodium metabisulfite, methyl hydroxybenzoate and propyl hydroxybenzoate. These additives may cause constriction or irritation to the airways if used as an inhalation. The Therapeutic Goods Administration (TGA) advises healthcare professionals who would have used Pfizer Gentamicin injection ampoules via inhalation to consider other therapies or request supply of a preservative-free gentamicin product via the Special Access Scheme (SAS).
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Pfizer on 1800 675 229 or your pharmacist at HPS Pharmacies.